Rechallenge with temozolomide in patients with recurrent gliomas

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neurology

• Publication date

  2009-02-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-009-5006-9PMID 19240962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma

  2008cited by this paper
• Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

  2007cited by this paper
• Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.

  2007cited by this paper
• Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

  2007cited by this paper
• Is protracted low-dose temozolomide feasible in glioma patients?

  2006cited by this paper
• Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

  2006cited by this paper
• Salvage temozolomide for prior temozolomide responders

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

  2004cited by this paper
• One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma

  2004influential reference
• Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

  2003cited by this paper
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

  2000influential reference
• Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

  1999cited by this paper
• Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

  1999cited by this paper
• Response criteria for phase II studies of supratentorial malignant glioma.

  1990cited by this paper
• Evaluation of malignant glioma patients during the postirradiation period.

  1979cited by this paper

• Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies

  2026cites this paper
• Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study.

  2026cites this paper
• Therapy-induced senescence of glioblastoma cells is determined by the p21CIP1-CDK1/2 axis and does not require activation of DREAM

  2025cites this paper
• Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood–Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment

  2025cites this paper
• Moving the Pendulum for Glioblastoma Treatment: One Injection at a Time

  2023cites this paper
• Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up

  2023cites this paper
• Design of carbon and graphene quantum dots based nanotheranostics applications for glioblastoma management: Recent advanced and future prospects

  2023cites this paper
• Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial

  2022cites this paper
• RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.

  2022cites this paper
• MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas

  2022cites this paper
• Low expression of CDHR1 is an independent unfavorable prognostic factor in glioma

  2021cites this paper
• A Hypoxia-Associated Prognostic Gene Signature Risk Model and Prognosis Predictors in Gliomas

  2021cites this paper
• Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells

  2021cites this paper
• Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma

  2021cites this paper
• Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients

  2020cites this paper
• Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts

  2020cites this paper
• Considering the Experimental Use of Temozolomide in Glioblastoma Research

  2020cites this paper
• Gliome

  2019cites this paper
• Stereotactic Radiosurgery for the Treatment of Recurrent High-grade Gliomas: Long-term Follow-up

  2019cites this paper
• DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.

  2019cites this paper
• Temozolomide rechallenge in recurrent glioblastoma: when is it useful?

  2018cites this paper
• Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?

  2018cites this paper
• Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma

  2018cites this paper
• Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide; Report of Three Cases and Review of the Literature.

  2017cites this paper
• Treatment options for recurrent high-grade gliomas.

  2017cites this paper
• Current Standards of Care in Glioblastoma Therapy

  2017cites this paper
• Median survival after various methods of Table 1 : Neuroimaging and glioblastoma : Macdonald versus RANO criteria

  2016influential citation
• Development of fluorescent biosensors and inhibitors to probe and target CDK5/p25 in glioblastoma

  2016cites this paper
• Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

  2016cites this paper
• Recurrent Glioblastoma: Where we stand

  2015cites this paper
• MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

  2015cites this paper
• MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Bene fi t from Dose-Intensi fi ed Temozolomide Rechallenge in Progressive Glioblastoma : The DIRECTOR Trial

  2015cites this paper
• ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation

  2015cites this paper
• Treating recurrent glioblastoma: an update.

  2015cites this paper
• Dose-dense Temozolomide: Is It Still Promising?

  2015cites this paper
• The future of high-grade glioma: Where we are and where are we going

  2015cites this paper
• Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma

  2015cites this paper
• Stereotactic laser ablation of high-grade gliomas.

  2014cites this paper
• Glioblastoma: Background, Standard Treatment Paradigms, and Supportive Care Considerations

  2014cites this paper
• Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.

  2014influential citation
• Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme

  2014cites this paper
• Emerging treatment strategies for glioblastoma multiforme

  2014cites this paper
• The role of neuropathology in the management of progressive glioblastoma

  2014cites this paper
• Dose-dense Temozolomide: Is It Still Promising?

  2014cites this paper
• The role of cytotoxic chemotherapy in the management of progressive glioblastoma

  2014cites this paper
• Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma

  2013cites this paper
• Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma

  2013cites this paper
• Drug rechallenge and treatment beyond progression—implications for drug resistance

  2013cites this paper
• Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.

  2013cites this paper
• Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.

  2013cites this paper
• Advances and challenges in the treatment of glioblastoma: a clinician's perspective.

  2013cites this paper
• Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.

  2013cites this paper
• Standards of care for treatment of recurrent glioblastoma--are we there yet?

  2013cites this paper
• Value of Nitrosourea-based Chemotherapy in Recurrent High Grade Glioma,NEMROCK Experience

  2013cites this paper
• “One week on–one week off”: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center

  2013influential citation
• Re-Irradiation in Recurrent High-Grade Glioma

  2013cites this paper
• Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI

  2012cites this paper
• A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy

  2012cites this paper
• Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

  2012cites this paper
• Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date

  2012cites this paper
• A novel treatment for glioblastoma: integrin

  2012cites this paper
• Intra-operative electron beam radiotherapy for newly diagnosed and recurrent malignant gliomas: feasibility and long-term outcomes

  2012cites this paper
• Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature

  2012cites this paper
• Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis

  2012cites this paper
• A novel treatment for glioblastoma: integrin inhibition

  2012cites this paper
• Immature and absolute platelet count changes and thrombocytopenia in malignant glioma

  2011cites this paper
• Chemotherapie bei Gliomen

  2011cites this paper
• Pathway inhibition: emerging molecular targets for treating glioblastoma.

  2011cites this paper
• Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study

  2011cites this paper
• Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

  2011influential citation
• A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG)

  2011cites this paper
• Rechallenge with temozolomide in recurrent glioma

  2011cites this paper
• Evolving strategies: future treatment of glioblastoma

  2011cites this paper
• Salvage therapy with single agent bendamustine for recurrent glioblastoma

  2011cites this paper
• Current concepts and management of glioblastoma

  2011cites this paper
• Advances in malignant glioma drug discovery

  2011cites this paper
• Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?

  2011cites this paper
• Therapeutic options for recurrent malignant glioma.

  2011cites this paper
• Evolution of care for patients with relapsed glioblastoma

  2011cites this paper
• Novel diagnostic and therapeutic approaches to malignant glioma.

  2011cites this paper
• Treatment of recurrent high-grade gliomas

  2011cites this paper
• Development and clinical applications of the time intensity curve shape analysis in dynamic contrast enhanced MRI: a pixel-by-pixel approach

  2011cites this paper
• Recurrent high-grade glioma: a diagnostic and therapeutic challenge

  2011cites this paper
• Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches.

  2011cites this paper
• [Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003-2009].

  2011cites this paper
• High-Grade Astrocytomas

  2011cites this paper
• Optimizing the use of alkylators in neuro-oncology

  2011cites this paper
• [High-grade gliomas in adults].

  2011cites this paper
• Generation and Validation of a Prognostic Score to Predict Outcome after Re-irradiation of Recurrent Glioma

  2011cites this paper
• Molecular diagnostics of gliomas: the clinical perspective

  2010cites this paper
• Neuentwicklungen in der Neuroonkologie

  2010cites this paper
• Strahlentherapie des Glioblastoms : Ergebnisse und prognostische Faktoren bei hyperfraktionierter und konventioneller Strahlentherapie

  2010cites this paper
• Neue Entwicklungen in der Gliomtherapie

  2010cites this paper
• Temozolomide and MGMT forever?

  2010cites this paper
• Vincristine in high-grade glioma.

  2010cites this paper
• Anaplastische Gliome

  2010cites this paper
• Temozolomide: Expanding its role in brain cancer.

  2010cites this paper
• MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

  2010cites this paper
• Medikamentöse Therapien bei Patienten mit rezidivierten Glioblastomen: Versuch einer Standortbestimmung

  2010cites this paper
• Standard therapy for glioblastoma--a review of where we are.

  2010cites this paper